Virus‐like particles: Next‐generation nanoparticles for targeted therapeutic delivery

Abstract Most drug therapies distribute the agents throughout the entire body, even though the drugs are typically only needed at specific tissues. This often limits dosage and causes discomfort and harmful side‐effects. Significant research has examined nanoparticles (NPs) for use as targeted delivery vehicles for therapeutic cargo, however, major clinical success has been limited. Current work focuses mainly on liposomal and polymer‐based NPs, but emerging research is exploring the engineering of viral capsids as noninfectious protein‐based NPs—termed virus‐like particles (VLPs). This review covers the research that has been performed thus far and outlines the potential for these VLPs to become highly effective delivery vehicles that overcome the many challenges encountered for targeted delivery of therapeutic cargo.

[1]  P. Butler.  Hepatitis B Virus (HBV): The Life-cycle and Assembly of a Complex Virus , 2007 .

[2]  S. Pincus,et al.  Coupling Peptide Antigens to Virus-Like Particles or to Protein Carriers Influences the Th1/Th2 Polarity of the Resulting Immune Response , 2016, Vaccines.

[3]  A. Zlotnick,et al.  Differential assembly of Hepatitis B Virus core protein on single- and double-stranded nucleic acid suggest the dsDNA-filled core is spring-loaded. , 2012, Virology.

[4]  M. Finn,et al.  Cell Targeting with Hybrid Qβ Virus‐Like Particles Displaying Epidermal Growth Factor , 2011, Chembiochem : a European journal of chemical biology.

[5]  Corwin M. Nycholat,et al.  Colorful virus-like particles: fluorescent protein packaging by the Qβ capsid. , 2011, Biomacromolecules.

[6]  Saber M Hussain,et al.  Metal-based nanoparticles and their toxicity assessment. , 2010, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[7]  C. Blum,et al.  Predicting the loading of virus-like particles with fluorescent proteins. , 2014, Biomacromolecules.

[8]  Rees F. Garmann,et al.  The assembly pathway of an icosahedral single-stranded RNA virus depends on the strength of inter-subunit attractions. , 2014, Journal of molecular biology.

[9]  Ting-Yi Wang,et al.  Improving the Endosomal Escape of Cell-Penetrating Peptides and Their Cargos: Strategies and Challenges , 2012, Pharmaceuticals.

[10]  Bradley C. Bundy,et al.  Efficient disulfide bond formation in virus-like particles. , 2011, Journal of biotechnology.

[11]  M. Young,et al.  Controlled ligand display on a symmetrical protein-cage architecture through mixed assembly. , 2006, Small.

[12]  Horst Kessler,et al.  Guiding plant virus particles to integrin-displaying cells. , 2012, Nanoscale.

[13]  P. Prevelige,et al.  Location of the bacteriophage P22 coat protein C-terminus provides opportunities for the design of capsid-based materials. , 2013, Biomacromolecules.

[14]  M. Baksh,et al.  Evolution and protein packaging of small-molecule RNA aptamers. , 2011, ACS nano.

[15]  T. Gedeon,et al.  Encapsulation of an enzyme cascade within the bacteriophage P22 virus-like particle. , 2014, ACS chemical biology.

[16]  John E. Johnson,et al.  Crystal Structure and Proteomics Analysis of Empty Virus-like Particles of Cowpea Mosaic Virus. , 2016, Structure.

[17]  John E. Johnson,et al.  Enhanced Local Symmetry Interactions Globally Stabilize a Mutant Virus Capsid That Maintains Infectivity and Capsid Dynamics , 2006, Journal of Virology.

[18]  A. Leslie,et al.  The crystal structure of the human hepatitis B virus capsid. , 1999, Molecular cell.

[19]  Ning Kang,et al.  Efficient encapsulation of Fe₃O₄ nanoparticles into genetically engineered hepatitis B core virus-like particles through a specific interaction for potential bioapplications. , 2015, Small.

[20]  John E. Johnson,et al.  Development of Bacteriophage P22 as a Platform for Molecular Display: Genetic and Chemical Modifications of the Procapsid Exterior Surface , 2008, Chembiochem : a European journal of chemical biology.

[21]  W. Gelbart,et al.  Packaging of a polymer by a viral capsid: the interplay between polymer length and capsid size. , 2008, Biophysical journal.

[22]  P. Pumpens,et al.  Preparation by alkaline treatment and detailed characterisation of empty hepatitis B virus core particles for vaccine and gene therapy applications , 2015, Scientific Reports.

[23]  P. Prevelige,et al.  Virus-like particle nanoreactors: programmed encapsulation of the thermostable CelB glycosidase inside the P22 capsid , 2012 .

[24]  Robert Langer,et al.  Nanoparticle delivery of cancer drugs. , 2012, Annual review of medicine.

[25]  John E. Johnson,et al.  P22 coat protein structures reveal a novel mechanism for capsid maturation: stability without auxiliary proteins or chemical crosslinks. , 2010, Structure.

[26]  A. Rynda-Apple,et al.  Symmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein. , 2015, ACS nano.

[27]  Rui Zhang,et al.  MS2 VLP-based delivery of microRNA-146a inhibits autoantibody production in lupus-prone mice , 2012, International journal of nanomedicine.

[28]  Hirenkumar K. Makadia,et al.  Poly Lactic-co-Glycolic Acid ( PLGA ) as Biodegradable Controlled Drug Delivery Carrier , 2011 .

[29]  Y. Zu,et al.  Oligonucleotide Aptamers: New Tools for Targeted Cancer Therapy , 2014, Molecular therapy. Nucleic acids.

[30]  J. Paulson,et al.  On-virus construction of polyvalent glycan ligands for cell-surface receptors. , 2008, Journal of the American Chemical Society.

[31]  Yuan Zhang,et al.  Development of a microRNA delivery system based on bacteriophage MS2 virus‐like particles , 2012, The FEBS journal.

[32]  B. Trus,et al.  Cargo-shell and cargo-cargo couplings govern the mechanics of artificially loaded virus-derived cages. , 2016, Nanoscale.

[33]  Trevor Douglas,et al.  Self-assembling biomolecular catalysts for hydrogen production. , 2016, Nature chemistry.

[34]  P. Stockley,et al.  MS2 viruslike particles: a robust, semisynthetic targeted drug delivery platform. , 2013, Molecular pharmaceutics.

[35]  W. Tan,et al.  Recombinant hepatitis B virus core particles: association, dissociation and encapsidation of green fluorescent protein. , 2008, Journal of virological methods.

[36]  R. Nolte,et al.  Controlled integration of polymers into viral capsids. , 2009, Biomacromolecules.

[37]  P. Prevelige,et al.  Site-directed coordination chemistry with P22 virus-like particles. , 2012, Langmuir : the ACS journal of surfaces and colloids.

[38]  Rees F. Garmann,et al.  Reconstituted plant viral capsids can release genes to mammalian cells. , 2013, Virology.

[39]  M. Francl.  Through the eyes of a chemist. , 2016, Nature chemistry.

[40]  Duane E. Prasuhn,et al.  Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[41]  J. Bruno.  A Review of Therapeutic Aptamer Conjugates with Emphasis on New Approaches , 2013, Pharmaceuticals.

[42]  P. Low,et al.  Principles in the design of ligand-targeted cancer therapeutics and imaging agents , 2015, Nature Reviews Drug Discovery.

[43]  Alan E. Rowan,et al.  Catalytic capsids: the art of confinement , 2011 .

[44]  Xue-Long Sun,et al.  Liposome surface functionalization based on different anchoring lipids via Staudinger ligation. , 2014, Organic & biomolecular chemistry.

[45]  M. Young,et al.  Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo , 2007, International journal of nanomedicine.

[46]  P. Prevelige,et al.  Selective biotemplated synthesis of TiO2 inside a protein cage. , 2015, Biomacromolecules.

[47]  Bradley C. Bundy,et al.  Escherichia coli‐based cell‐free synthesis of virus‐like particles , 2008, Biotechnology and bioengineering.

[48]  M. Francis,et al.  Osmolyte-mediated encapsulation of proteins inside MS2 viral capsids. , 2012, ACS nano.

[49]  K. Schwarz,et al.  Nonmethylated CG Motifs Packaged into Virus-Like Particles Induce Protective Cytotoxic T Cell Responses in the Absence of Systemic Side Effects , 2004, The Journal of Immunology.

[50]  J. O’Neil,et al.  PET Imaging and biodistribution of chemically modified bacteriophage MS2. , 2013, Molecular pharmaceutics.

[51]  Mark B. Carter,et al.  Cell-specific delivery of diverse cargos by bacteriophage MS2 virus-like particles. , 2011, ACS nano.

[52]  N. Steinmetz,et al.  Hydrazone ligation strategy to assemble multifunctional viral nanoparticles for cell imaging and tumor targeting. , 2010, Nano letters.

[53]  N. Steinmetz,et al.  Infusion of imaging and therapeutic molecules into the plant virus-based carrier cowpea mosaic virus: cargo-loading and delivery. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[54]  Trevor Douglas,et al.  Tailored delivery of analgesic ziconotide across a blood brain barrier model using viral nanocontainers , 2015, Scientific Reports.

[55]  B. Wiedenheft,et al.  Programmed Self-Assembly of an Active P22-Cas9 Nanocarrier System. , 2016, Molecular pharmaceutics.

[56]  Mark Thomas Smith,et al.  Reengineering viruses and virus-like particles through chemical functionalization strategies. , 2013, Current opinion in biotechnology.

[57]  Marianne Manchester,et al.  Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. , 2007, Chemistry & biology.

[58]  Jan C M van Hest,et al.  Functionalization of protein-based nanocages for drug delivery applications. , 2014, Nanoscale.

[59]  N. Steinmetz,et al.  Increased tumor homing and tissue penetration of the filamentous plant viral nanoparticle Potato virus X. , 2013, Molecular pharmaceutics.

[60]  Dennis E Discher,et al.  Minimal " Self " Peptides That Inhibit Phagocytic Clearance and Enhance Delivery of Nanoparticles References and Notes , 2022 .

[61]  A. Zlotnick,et al.  Interaction with capsid protein alters RNA structure and the pathway for in vitro assembly of cowpea chlorotic mottle virus. , 2004, Journal of molecular biology.

[62]  Lauren M. Huyett,et al.  The RNA core weakly influences the interactions of the bacteriophage MS2 at key environmental interfaces , 2011 .

[63]  Mauro Ferrari,et al.  Principles of nanoparticle design for overcoming biological barriers to drug delivery , 2015, Nature Biotechnology.

[64]  Corwin M. Nycholat,et al.  Glycan-targeted virus-like nanoparticles for photodynamic therapy. , 2012, Biomacromolecules.

[65]  M. G. Finn,et al.  Chemical Synthesis of GM2 Glycans, Bioconjugation with Bacteriophage Qβ, and the Induction of Anticancer Antibodies , 2016, Chembiochem : a European journal of chemical biology.

[66]  Kedar G. Patel,et al.  Surface functionalization of virus-like particles by direct conjugation using azide-alkyne click chemistry. , 2011, Bioconjugate chemistry.

[67]  D. Reinhoudt,et al.  Self-assembly triggered by self-assembly: optically active, paramagnetic micelles encapsulated in protein cage nanoparticles. , 2014, Journal of inorganic biochemistry.

[68]  M. Young,et al.  Chemical modification of a viral cage for multivalent presentation. , 2002, Chemical communications.

[69]  Nicole F Steinmetz,et al.  Applications of viral nanoparticles in medicine. , 2011, Current opinion in biotechnology.

[70]  J. O’Neil,et al.  Genome-free Viral Capsids as Carriers for Positron Emission Tomography Radiolabels , 2008, Molecular Imaging and Biology.

[71]  Wei Wang,et al.  Development of an antisense RNA delivery system using conjugates of the MS2 bacteriophage capsids and HIV-1 TAT cell-penetrating peptide. , 2009, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[72]  P. Prevelige,et al.  Use of the interior cavity of the P22 capsid for site-specific initiation of atom-transfer radical polymerization with high-density cargo loading. , 2012, Nature chemistry.

[73]  L. Rasochova,et al.  Inactivation and purification of cowpea mosaic virus-like particles displaying peptide antigens from Bacillus anthracis. , 2007, Journal of virological methods.

[74]  Samir Mitragotri,et al.  Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. , 2007, Journal of controlled release : official journal of the Controlled Release Society.

[75]  Duane E. Prasuhn,et al.  Plasma clearance of bacteriophage Qbeta particles as a function of surface charge. , 2008, Journal of the American Chemical Society.

[76]  John J. Rossi,et al.  Cell-type-specific, Aptamer-functionalized Agents for Targeted Disease Therapy , 2014, Molecular therapy. Nucleic acids.

[77]  Herbert J Meiselman,et al.  Antibody against poly(ethylene glycol) adversely affects PEG‐asparaginase therapy in acute lymphoblastic leukemia patients , 2007, Cancer.

[78]  N. Steinmetz,et al.  Development of viral nanoparticles for efficient intracellular delivery. , 2012, Nanoscale.

[79]  A. Zlotnick,et al.  Full-Length Hepatitis B Virus Core Protein Packages Viral and Heterologous RNA with Similarly High Levels of Cooperativity , 2010, Journal of Virology.

[80]  G. Lin,et al.  Using a Novel MicroRNA Delivery System to Inhibit Osteoclastogenesis , 2015, International journal of molecular sciences.

[81]  G. Pillai,et al.  Nanomedicines for Cancer Therapy : An Update of FDA Approved and Those under Various Stages of Development , 2014 .

[82]  D. Peabody,et al.  Affinity selection of epitope-based vaccines using a bacteriophage virus-like particle platform. , 2015, Current opinion in virology.

[83]  K. Breitenkamp,et al.  Encapsidated Atom-Transfer Radical Polymerization in Qβ Virus-like Nanoparticles , 2014, ACS nano.

[84]  Neil R. Voss,et al.  Engineered mutations change the structure and stability of a virus-like particle. , 2012, Biomacromolecules.

[85]  Lars Liljas,et al.  The crystal structure of bacteriophage Qβ at 3.5 å resolution , 1996 .

[86]  Allie C. Obermeyer,et al.  Rapid chemoselective bioconjugation through oxidative coupling of anilines and aminophenols. , 2011, Journal of the American Chemical Society.

[87]  Trevor Douglas,et al.  Rescuing recombinant proteins by sequestration into the P22 VLP. , 2013, Chemical communications.

[88]  G. Lomonossoff,et al.  Efficient generation of cowpea mosaic virus empty virus-like particles by the proteolytic processing of precursors in insect cells and plants. , 2009, Virology.

[89]  C. Thaxton,et al.  Update on current and potential nanoparticle cancer therapies , 2013, Current opinion in oncology.

[90]  C. Tisné,et al.  Co-expression of RNA–protein complexes in Escherichia coli and applications to RNA biology , 2013, Nucleic acids research.

[91]  Wei Chan,et al.  Escherichia coli‐based cell free production of flagellin and ordered flagellin display on virus‐like particles , 2013, Biotechnology and bioengineering.

[92]  R. Sodoyer,et al.  Scalable chromatography-based purification of virus-like particle carrier for epitope based influenza A vaccine produced in Escherichia coli. , 2016, Journal of virological methods.

[93]  P. Cullis,et al.  Liposomal drug delivery systems: from concept to clinical applications. , 2013, Advanced drug delivery reviews.

[94]  M. Nassal,et al.  Packaging of up to 240 subunits of a 17 kDa nuclease into the interior of recombinant hepatitis B virus capsids , 2000, FEBS letters.

[95]  Duane E. Prasuhn,et al.  Viral MRI contrast agents: coordination of Gd by native virions and attachment of Gd complexes by azide-alkyne cycloaddition. , 2007, Chemical communications.

[96]  In‐San Kim,et al.  Bioengineered protein-based nanocage for drug delivery. , 2016, Advanced drug delivery reviews.

[97]  Inge J. Minten,et al.  Controlled encapsulation of multiple proteins in virus capsids. , 2009, Journal of the American Chemical Society.

[98]  Sonny C. Hsiao,et al.  Viral capsid DNA aptamer conjugates as multivalent cell-targeting vehicles. , 2009, Journal of the American Chemical Society.

[99]  M. Finn,et al.  Accelerated bioorthogonal conjugation: a practical method for the ligation of diverse functional molecules to a polyvalent virus scaffold. , 2005, Bioconjugate chemistry.

[100]  N. Steinmetz,et al.  PEGylated viral nanoparticles for biomedicine: the impact of PEG chain length on VNP cell interactions in vitro and ex vivo. , 2009, Biomacromolecules.

[101]  M. Finn,et al.  Systemic trafficking of plant virus nanoparticles in mice via the oral route. , 2005, Virology.

[102]  J. Cornelissen,et al.  Versatile post-functionalization of the external shell of cowpea chlorotic mottle virus by using click chemistry. , 2014, Organic & biomolecular chemistry.

[103]  Andrew K. Udit,et al.  Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds. , 2010, Chemistry & biology.

[104]  B. Schwarz,et al.  Two-Dimensional Crystallization of P22 Virus-Like Particles. , 2016, The journal of physical chemistry. B.

[105]  Maarten van Iterson,et al.  Integrated analysis of microRNA and mRNA expression: adding biological significance to microRNA target predictions , 2013, Nucleic acids research.

[106]  P. Prevelige,et al.  Genetically programmed in vivo packaging of protein cargo and its controlled release from bacteriophage P22. , 2011, Angewandte Chemie.

[107]  Jason Coleman,et al.  Emerging technologies of polymeric nanoparticles in cancer drug delivery , 2011 .

[108]  John E. Johnson,et al.  New addresses on an addressable virus nanoblock; uniquely reactive Lys residues on cowpea mosaic virus. , 2004, Chemistry & biology.

[109]  G. Lomonossoff,et al.  Cowpea mosaic virus unmodified empty viruslike particles loaded with metal and metal oxide. , 2010, Small.

[110]  M G Finn,et al.  RNA-directed packaging of enzymes within virus-like particles. , 2010, Angewandte Chemie.

[111]  P. Ray,et al.  Aptamers for Targeted Drug Delivery , 2010, Pharmaceuticals.

[112]  Nicole F Steinmetz,et al.  Intravital imaging of human prostate cancer using viral nanoparticles targeted to gastrin-releasing Peptide receptors. , 2011, Small.

[113]  Nicole F Steinmetz,et al.  Engineering of Brome mosaic virus for biomedical applications. , 2012, RSC advances.

[114]  D. Tullman-Ercek,et al.  Production and applications of engineered viral capsids , 2014, Applied Microbiology and Biotechnology.

[115]  Andries Zijlstra,et al.  Viral nanoparticles as tools for intravital vascular imaging , 2006, Nature Medicine.

[116]  Jacob M Hooker,et al.  Dual-surface-modified bacteriophage MS2 as an ideal scaffold for a viral capsid-based drug delivery system. , 2007, Bioconjugate chemistry.

[117]  William M. Gelbart,et al.  Self-Assembly of Viral Capsid Protein and RNA Molecules of Different Sizes: Requirement for a Specific High Protein/RNA Mass Ratio , 2011, Journal of Virology.

[118]  V. Torchilin,et al.  New Developments in Liposomal Drug Delivery. , 2015, Chemical reviews.

[119]  John E. Johnson,et al.  Chemical conjugation of heterologous proteins on the surface of Cowpea mosaic virus. , 2004, Bioconjugate chemistry.

[120]  F. Chang,et al.  Direct comparison of liposomal doxorubicin with or without polyethylene glycol coating in C-26 tumor-bearing mice: is surface coating with polyethylene glycol beneficial? , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[121]  Martin G Pomper,et al.  State-of-the-art in design rules for drug delivery platforms: lessons learned from FDA-approved nanomedicines. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[122]  Qian Wang,et al.  Self-assembly and cross-linking of bionanoparticles at liquid-liquid interfaces. , 2005, Angewandte Chemie.

[123]  R. Quaife,et al.  Enhanced Radiofrequency Ablation With Magnetically Directed Metallic Nanoparticles , 2016, Circulation. Arrhythmia and electrophysiology.

[124]  John M Lambert,et al.  Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. , 2008, Cancer research.

[125]  Liang Shan,et al.  An Anti‐PSMA Bivalent Immunotoxin Exhibits Specificity and Efficacy for Prostate Cancer Imaging and Therapy , 2013, Advanced healthcare materials.

[126]  N. Stephanopoulos,et al.  Dual-surface modified virus capsids for targeted delivery of photodynamic agents to cancer cells. , 2010, ACS nano.

[127]  P. Prevelige,et al.  Implementation of p22 viral capsids as nanoplatforms. , 2010, Biomacromolecules.

[128]  S. Schmid,et al.  Multivalent Display and Receptor‐Mediated Endocytosis of Transferrin on Virus‐Like Particles , 2010, Chembiochem : a European journal of chemical biology.

[129]  Rong-Kun Chang,et al.  Pharmaceutical development and regulatory considerations for nanoparticles and nanoparticulate drug delivery systems. , 2013, Journal of pharmaceutical sciences.

[130]  J. Ai,et al.  Fabrication of coated-collagen electrospun PHBV nanofiber film by plasma method and its cellular study , 2011 .

[131]  John E. Johnson,et al.  Generation and structural analysis of reactive empty particles derived from an icosahedral virus. , 2006, Chemistry & biology.

[132]  T. Douglas,et al.  Developing a Dissociative Nanocontainer for Peptide Drug Delivery , 2015, International journal of environmental research and public health.

[133]  Karen L Wooley,et al.  Design of polymeric nanoparticles for biomedical delivery applications. , 2012, Chemical Society reviews.

[134]  Alaa A. A. Aljabali,et al.  CPMV-DOX delivers. , 2013, Molecular pharmaceutics.

[135]  L. Liljas,et al.  Structure and stability of icosahedral particles of a covalent coat protein dimer of bacteriophage MS2 , 2009, Protein science : a publication of the Protein Society.

[136]  K. Tārs,et al.  Assembly of mixed rod-like and spherical particles from group I and II RNA bacteriophage coat proteins. , 2009, Virology.

[137]  Wei Chan,et al.  Assessing sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold for vaccines and drug delivery , 2015, Proceedings of the National Academy of Sciences.

[138]  D. Stuart,et al.  Tandem Fusion of Hepatitis B Core Antigen Allows Assembly of Virus-Like Particles in Bacteria and Plants with Enhanced Capacity to Accommodate Foreign Proteins , 2015, PloS one.

[139]  Nico A J M Sommerdijk,et al.  A virus-based single-enzyme nanoreactor. , 2007, Nature nanotechnology.

[140]  Philippe Leboulch,et al.  Highly efficient in vitro and in vivo delivery of functional RNAs using new versatile MS2-chimeric retrovirus-like particles , 2015, Molecular therapy. Methods & clinical development.

[141]  Peter G Stockley,et al.  Engineering thermal stability in RNA phage capsids via disulphide bonds. , 2005, Journal of nanoscience and nanotechnology.

[142]  P. Prevelige,et al.  Nanoreactors by programmed enzyme encapsulation inside the capsid of the bacteriophage P22. , 2012, ACS nano.

[143]  Christopher M. Jakobson,et al.  Influence of Electrostatics on Small Molecule Flux through a Protein Nanoreactor. , 2015, ACS synthetic biology.

[144]  D. Neri,et al.  Antibody-Drug Conjugates and Small Molecule-Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents. , 2015, Journal of medicinal chemistry.

[145]  M. Bachmann,et al.  Cutting Edge: IL-21 and TLR Signaling Regulate Germinal Center Responses in a B Cell-Intrinsic Manner , 2010, The Journal of Immunology.

[146]  Jo Wixon,et al.  Gene therapy clinical trials worldwide to 2012 – an update , 2013, The journal of gene medicine.

[147]  M. Goldenberg.  Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer. , 1999, Clinical therapeutics.